dc.contributor.author | Makowska, Marta | |
dc.date.accessioned | 2016-10-10T07:32:36Z | |
dc.date.available | 2016-10-10T07:32:36Z | |
dc.date.issued | 2016-09-15 | |
dc.identifier.issn | 1899-2226 | |
dc.identifier.uri | http://hdl.handle.net/11089/19845 | |
dc.description.abstract | For many years, the subject of aggressive marketing campaigns conducted by pharmaceutical
companies has been raised in Poland. Drug ads are everywhere, on television,
the radio, magazines and on the Internet. Therefore, it is extremely important
is to ensure both their legal and ethical dimension.
In my article I will present the differences between direct-to-consumer advertising
of medicines in Poland and in the US. The dissimilarities result mainly from
differences in legislation. In Poland the law is much stricter than in the US. For
example, in the United States companies are allowed to advertise prescription drugs
directly to patients. In the whole of the European Union, and thus in Poland, it is
strictly prohibited.
The article will present other regulations existing in Poland and in the United
States and it will compare them. It will show examples of violations of the law and
ethics in the advertising of medicine in both countries. It will briefly outline the
negative consequences of unacceptable pharmaceutical marketing. | pl_PL |
dc.language.iso | pl | pl_PL |
dc.publisher | Lodz University Press | pl_PL |
dc.relation.ispartofseries | Annales. Etyka w Życiu Gospodarczym;3 | |
dc.subject | pharmaceutical industry | pl_PL |
dc.subject | advertisement | pl_PL |
dc.subject | drugs | pl_PL |
dc.subject | law | pl_PL |
dc.subject | ethics | pl_PL |
dc.title | Kontrowersje związane z reklamowaniem leków Analiza porównawcza Polski i Stanów Zjednoczonych | pl_PL |
dc.title.alternative | Controversial Advertising of Medicines. A Comparison between Poland and the United States | pl_PL |
dc.type | Article | pl_PL |
dc.page.number | 155–168 | pl_PL |
dc.contributor.authorAffiliation | Warsaw University of Life Sciences | pl_PL |
dc.identifier.eissn | 2353-4869 | |
dc.references | Arnold D., J. Oakley, The Politics and Strategy of Industry Self-Regulation: The Pharmaceutical Industry's Principles for Ethical Direct-to-Consumer Advertising as a Deceptive Blocking Strategy, „Journal of Health Politics, Policy and Law” 2013, vol. 38, nr 3, s. 505–544. | pl_PL |
dc.references | ASRC, NARB Panel Recommends Novartis Discontinue Claims that Excedrin Starts Relieving Headache Pain Faster than Advil Claims at Issue Challenged by Pfizer Consumer Healthcare, 2012, http://www.asrcreviews.org/2012/01/narb-panel-recommends-novartis-discontinue-claims-that-excedrin-starts-relieving-headache-pain-faster-thanadvil-claims-at-issue-challenged-by-pfizer-consumer-healthcare/. | pl_PL |
dc.references | Blinkoff, S., K. Tabela, USA – Pharmaceutical Advertising 2015. International Comparative Legal Guides, 2015, http://www.iclg.co.uk/practice-areas/pharmaceutical-advertising/pharmaceutical-advertising-2015/usa. | pl_PL |
dc.references | Chaniecka K.A., A. Czerw, Płeć a postrzeganie reklamy telewizyjnej leków OTC, „Hygeia Public Health” 2013, nr 48, s. 509–514. | pl_PL |
dc.references | CHPA, OTC Drug Advertising, 2015 http://www.chpa.org/OTCDrugAdvertising.aspx. | pl_PL |
dc.references | Diehl S, B. Mueller, R. Terlutter, Consumer Responses Towards Non-Prescription and Prescription Drug Advertising in the US and Germany: They Don’t Really Like It, but They Do Believe It, „International Journal of Advertising” 2008, nr 27(1), s. 99–131. | pl_PL |
dc.references | Donohue J., A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection, „The Milbank Quarterly” 2006, nr 84, s. 659–699. | pl_PL |
dc.references | Dz.U. 1991 nr 105 poz. 452, Ustawa o środkach farmaceutycznych, materiałach medycznych, aptekach, hurtowniach i nadzorze farmaceutycznym. | pl_PL |
dc.references | Dz.U. 1993 nr 47 poz. 211, Ustawa o zwalczaniu nieuczciwej konkurencji. | pl_PL |
dc.references | Dz.U. 2008 nr 45 poz. 271, Prawo Farmaceutyczne. | pl_PL |
dc.references | Faerber A.E., D.H. Kreling, Content Analysis of False and Misleading Claims in Television Advertising for Prescription and Nonprescription Drugs, „Journal of General Internal Medicine” 2012, nr 29, s. 110–118. | pl_PL |
dc.references | FDA, Cipher Pharmaceuticals Inc. Warning Letter, 2014, http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ UCM415228.pdf. | pl_PL |
dc.references | FDA, Drug Applications for Over-the-Counter (OTC) Drugs, 2015, http://www.fda.gov/ drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalap plications/over-the-counterdrugs/default.htm. | pl_PL |
dc.references | FDA, Inspections, Compliance, Enforcement, and Criminal Investigations, Warrning Letters, Drugs, 2015, http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInfor mation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/default.htm. | pl_PL |
dc.references | FDA, Prescription Drug Advertising, http://www.fda.gov/Drugs/ResourcesForYou/Consu mers/PrescriptionDrugAdvertising/default.htm. | pl_PL |
dc.references | Główny Inspektorat Farmaceutyczny, Decyzje i komunikaty, https://www.gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/decyzje. | pl_PL |
dc.references | Główny Inspektorat Farmaceutyczny, Decyzja z dnia 31.01.2011, znak: GIF-P-R-450/106- 4/JD/10/11, 2011, https://www.gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/archiwum/ wstrzymanie-reklam/80,Rok-2011.html. | pl_PL |
dc.references | Główny Inspektorat Farmaceutyczny, Decyzja z dnia 26.04.2012, znak: GIF-P-R-450/14-2/JD/ 12,2012, https://www.gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/archiwum/wstrzymanie-reklam/79,Rok-2012.html. | pl_PL |
dc.references | Główny Inspektorat Farmaceutyczny, Decyzja z dnia 11.09.2014, znak: GIF-P-R-450/46-2/JD/ 14, 2014, https://www.gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/decyzje/619,Decyzja-z-dnia-11092014-znak-GIF-P-R-45046-2JD14.html. | pl_PL |
dc.references | Frosch D., P.M. Kruger, R.C. Hornik, P. Cronholm, F. Barg, Creating Demand for Prescription Drugs: A Content Analysis of Television Direct-to-Consumer Advertising, „Annals of Family Medicine” 2007, nr 1(5), s. 6–13. | pl_PL |
dc.references | KPMG i IAA, Rynek reklamy telewizyjnej w Polsce po latach wychodzi na prostą, Warszawa 2015. | pl_PL |
dc.references | Kravitz R.L., Direct-to-Consumer Advertising of Prescription Drugs, „The Western Journal of Medicine” 2000, nr 173(4), s. 221–222. | pl_PL |
dc.references | Kula P., Pharmaexpert podsumowuje rynek apteczny w 2014 roku, 2015, http://www.aptekarzpolski.pl/index.php?option=com_content&task=view&id=1850&Itemid=79. | pl_PL |
dc.references | Mack J., Increased DTC Advertising and Rising Drug Prices – Is There a Causal Link?, 2015, http://pharmamkting.blogspot.com/2015/11/increased-dtc-advertising-and-rising.html. | pl_PL |
dc.references | Makowska M., Etyczne standardy marketingu farmaceutycznego, CeDeWu, Warszawa 2010. | pl_PL |
dc.references | Makowska M., Etyczne wyzwania współpracy studentów medycyny z przemysłem farmaceutycznym. Studium porównawcze sytuacji w USA i Polsce, Wydawnictwo SGGW, Warszawa 2016. | pl_PL |
dc.references | Marketing przy kawie, Koncerny farmaceutyczne mocno inwestują w reklamę. Aflofarm na czele peletonu, 2014, http://www.marketing-news.pl/theme.php?art=1804. | pl_PL |
dc.references | Michalski B., Ł. Sławatyniec, M. Duczyńska, K. Kęska, Prawo farmaceutyczne i refundacja leków, Walters Kluwer, Warszawa 2013. | pl_PL |
dc.references | Mogull, S.A., Chronology of Direct-to-Customer Advertising Regulation in the United States, „American Medical Writers Association Journal” 2008, nr 23(3), s. 106–109. | pl_PL |
dc.references | PAIiIZ, Sektor faramaceutyczny i biotechnologiczny w Polsce, Polska Agencja Informacji i Inwestycji Zagranicznych SA, Warszawa 2013. | pl_PL |
dc.references | Rada Reklamy, Komisja Etyki Reklamy, https://www.radareklamy.pl/komisja-etyki-reklamy. | pl_PL |
dc.references | Rada Reklamy, Uchwała Nr ZO 40/11 w sprawie reklamy firmy Novartis Poland Sp. z o.o., 2011, https://www.radareklamy.pl/uchwaly-ker/2011/uchwa%C5%82a-nr-zo-40-11 -w-sprawie-reklamy-firmy-novartis-poland-sp-z-o-o. | pl_PL |
dc.references | Rada Reklamy, Uchwała Nr ZO 64/14 w sprawie reklamy firmy Pfizer Trading Polska Sp. z o.o., 2014, https://www.radareklamy.pl/uchwaly-ker/2014/uchwa%C5%82a-nr-zo -64-14-w-sprawie-reklamy-firmy-pfizer-trading-polska-sp-z-o-o. | pl_PL |
dc.references | Stange K.C., Time to Ban Direct-to-Consumer Prescription Drug Marketing, „Annals of Family Medicine” 2007, nr 5(2), s. 101–104. | pl_PL |
dc.references | Szuba T., Ekonomka leku. Podręcznik dla studentów farmacji i farmaceutów, „Aptekarz” 2003, vol. 11, nr 10, s. 257–292. | pl_PL |
dc.references | Szuba T., Polityka leku w Polsce. „Aptekarz” 1994, vol. 2, nr 9, s. 379–386. | pl_PL |
dc.references | Sudak I., My, Polacy, lekomani. Rekordowe wydatki na leki, groźne skutki reklam, „Gazeta Wyborcza” 2015, http://wyborcza.biz/biznes/1,100896,17513743,My__Polacy__lekomani__Rekordowe_wydatki_na_leki__grozne.html#ixzz3uwzWsiDa. | pl_PL |
dc.references | Ventola C., Direct-to-Consumer Pharmaceutical Advertising. Therapeutic or Toxic?, „Pharmacy and Therapeutics” 2011, nr 10(36), s. 669–684. | pl_PL |
dc.references | Zarzeczna-Baran M., E. Bandurska, J. Pęgiel-Kamrat, A. Lewandowska, Wpływ reklamy na zakup leków dostępnych bez recepty, „Annales Academiae Medicae Gedanensis”, 2013, nr 43, s. 77–87. | pl_PL |
dc.contributor.authorEmail | marta_makowska@sggw.pl | pl_PL |
dc.identifier.doi | 10.18778/1899-2226.19.3.13 | |
dc.relation.volume | 19 | pl_PL |
dc.subject.jel | I18 | |
dc.subject.jel | M31 | |
dc.subject.jel | M38 | |